MITTO-AG
Mitto AG, a global SMS mobile messaging provider, has today released a new white paper, “Driving Business Through A2P Messaging.” The paper, authored by Juniper Research, a global leader for industry research and data, provides a comprehensive overview of how Mobile Network Operators, OTTs and Enterprises can use A2P messaging and its associated use cases to drive business and realize increased revenues.
Key findings include:
- Consumer affinity with text messaging now extends to its A2P incarnation suggesting that the market has been seeded for additional use cases.
- A2P messaging provides Mobile Network Operators with an opportunity to plug a growing cost-revenue deficit being caused by declining core revenues from voice, P2P messaging and data and increasing capex and opex costs.
- While A2P messaging generated traffic worth nearly $36.3 billion in 2016, 31 percent of that traffic was grey route and not monetized, totaling nearly $11.9 billion in lost revenues to Mobile Network Operators.
- OTT players are heavy users of A2P messaging, generating billions of traffic per annum in their use of A2P messaging for 2FA (two-factor authentication) and to re-engage users who have abandoned their messaging application or changed device.
- The greatest financial benefit that A2P messaging can deliver to OTTs that provide content is in the form of an alternative billing mechanism with the value of digital content paid for via carrier billing projected to increase from $16.5 billion in 2016 to nearly $56.2 billion in 2021, an average annual growth of 28 percent.
- Consumers prefer SMS as a means of communicating with companies over other channels including OTT messaging apps, Facebook/Skype and push notifications direct to a company’s app.
The white paper concludes with a series of recommendations from Juniper Research on the steps these three industries should take to increase revenues from A2P messaging. Those include the requirement to use carrier-grade messaging platforms or work with third party platform providers that can help stem grey route traffic and increase reach to deliver a robust and reliable global SMS connectivity offering.
“While companies know that the A2P opportunity is there, we find that more often than not, they don’t know how to take advantage of it for their own business benefits,” comments Andrea Giacomini, Managing Director, Mitto. “That’s why we engaged Juniper to write this white paper, to provide simple recommendations that companies can quickly implement to rapidly start realizing results from the mechanism.”
The white paper is available for complimentary download at http://go.mitto.ch/A2P_messaging_whitepaper .
About Mitto
With Headquarters in Zug, Switzerland and offices around the world, Mitto’s agile approach, trusted mobile operator relationships and carrier-grade SMS Messaging platform improve conversions and increase the speed and reliability of global mobile communications for the world’s largest OTTs, Enterprise and Mobile Operators. For more information visit mitto.ch , follow us on LinkedIn , Twitter or like us on Facebook .
View source version on businesswire.com: http://www.businesswire.com/news/home/20170403006595/en/
Contact:
Mitto AG
Louise Finlay, +1 305-343-9122
louise@mitto.ch
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release
Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom